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Abstract
Eosinophilic digestive disease (EDD) includes a broad spectrum of clinical presentations due to eosinophilic
inflammation involving anywhere from the esophagus to the rectum.
The heterogeneity in the clinical presentations of EDD is determined by the site and depth of eosinophilic
infiltration. The sites of inflammation determine the nomenclature for EDD. The most well characterized of these,
eosinophilic esophagitis (EE), eosinophilic gastroenteritis (EG), and eosinophilic colitis or enterocolitis. While the
depth of esosinophilic infiltration through the three main layers (mucosa, musculosa and serosa) determines the
prominent clinical manifestation. The recent advances in gastrointestinal endoscopy and the increasing awareness
and diagnosis of EDD, in my viewpoint, can be of help to add to our understanding of the heterogeneous clinical
syndrome under the broad title bronchial asthma.
Here I present my viewpoint that EDD and the allergic bronchial asthma can be regarded as two clinical
expressions of one disease in two different but related anatomical systems.
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Recently, Eosinophilic Digestive Disease has become the
focus of many published articles as well as discussions
in scientific conferences[1,2]. The recent great advances
in technology in the gastrointestinal endoscopy with
more accessibility to highly versatile upper, lower as
well as video-capsule endoscopes that can enable us to
visualize and study every part of the alimentary canal,
have revolutionized our understanding and researches in
the digestive system to more clearly differentiate dis-
eases with similar clinical pictures on basis of pathology
and pathogenesis.
The common clinical presentations of abdominal pain,
dyspepsia, bowel habits changes, nausea, vomiting,
malabsorption and protein wasting can now be more
accurately diagnosed on basis of pathology and patho-
genesis. But in spite of that, my observation is that EDD
is still under-diagnosed, as many cases of what I call
mild intermittent attacks pass undiagnosed with empiri-
cal symptomatic treatment, or even misdiagnosed as
gastroesophageal reflux disease (GERD) or irritable
bowel syndrome (IBS),..etc.
Eosinophilic digestive disease (EDD) includes a broad
spectrum of clinical presentations due to eosinophilic
inflammation involving anywhere from the esophagus to
the rectum [1,2].
The heterogeneity in the clinical presentations of EDD
is determined by the site and depth of eosinophilic infil-
tration. The sites of inflammation determine the nomen-
clature for EDD. The most well characterized of these
are eosinophilic esophagitis (EE), eosinophilic gastroen-
teritis (EG), and eosinophilic colitis or enterocolitis.
While the depth of esosinophilic infiltration through the
three main layers (mucosa, musculosa and serosa) deter-
mines the prominent clinical manifestation, for example,
infiltration to the musculosa will be manifested by dys-
phagia in EE, or severe colic up to a picture of intestinal
obstruction in EG and E enterocolitis. While subserosal
and serosal affection will be manifested by ascites with
abundant of eosinophils [3-6].
Tissue and blood eosinophilia (eosinophilic disorders)
were broadly classified by Simons [7] according to the Correspondence: yakoot@yahoo.com
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ways. The intrinsic (eosinophils/or precursors) mutation
mediated clonal expansion pathway; such as in some
cases of leukemia and myeloproliferative diseases. The
second pathway is the cytokine-mediated or extrinsic
pathway. Interleukin-5 (IL-5) and to a lesser degree IL-3
a n dG M - C S Fa r et h em o s tc r i tical cytokines mediating
increased eosinophils differentiation, activation, and sur-
vival [7]. T helper-2 (TH2) inflammatory responses are
induced by a variety of factors including allergic disor-
ders, drug reaction with eosinophilia and in certain
infections particularly by helminthes (worms). These
responses are characterized by IgE antibody production
and IL-5 induced eosinophilia [7].
Similar to allergic bronchial asthma, recent investiga-
tions support the allergen driven TH2 cytokine-
mediated eosinophilic inflammation as the pathophysio-
logic mechanism of the EDD disease [1,2,4,8].
Whether the primary offender is an extrinsic one like
an allergen taken by mouth or an intrinsic one like in
case of parasitic infections, we are in favor to consider
EDD as one disease.
The rationale behind this lies in our “unpublished
observations” in 2 cases presenting with a full picture of
EDD with abdominal pain, protein wasting, ascites with
eosinophilia detected in peripheral blood, ascitic fluid as
well as in biopsy tissues from lower endoscopy. The
offending cause in these cases had been found to be
parasitic infection by fascioliasis in the early migratory
hepatic phase. The dramatic response to a course of sys-
temic corticosteroids after the persistence of manifesta-
tions in spite of the treatment of fascioliasis, plus the
typical picture of a multilayer eosinophilic enterocolitis,
and the associated history of other atopic diseases have
urged us to consider the term “intrinsic” rather than
“secondary” EDD which hints to more heterogeneous
pathogenetic factors for eosinophilia.
The recent advances in gastrointestinal endoscopy and
the increasing awareness and diagnosis of EDD, in our
mind, can be of help to add to our understanding of the
heterogeneous clinical syndrome under the broad title
bronchial asthma which remains a genuine medical mys-
tery [9]. There is a need for more differentiation of cases
on the basis of more homogeneous pathogenesis and
pathology rather than the current definitions which are
based mainly on the clinical manifestations leading to
the inclusion of highly heterogeneous groups with many
differing phenotypes, endotypes and response to treat-
ment under one diagnosis [8-10].
There is no reason in my opinion, so far, to consider the
allergic bronchial asthma or (the eosinophilic phenotype),
and the eosinophilic bronchitis as two separate entities but
we would rather explain this as in case of EDD on basis of
the depth of eosinophilic and mast cell infiltration in the
layers of the bronchial tissue whether to the layer of
smooth muscle leading to asthma or just in mucosa and
submucosa manifested as bronchitis [11,12].
Likewise the allergic rhinitis and allergic bronchial
asthma can be regarded as one disease manifested in
one system but in two different sites, like the case of EE
and EG.
Further more with this view, the EDD and the allergic
bronchial asthma can be regarded as two clinical expres-
sions of one disease in two different but related anato-
mical systems, adding the fact that the embryological
origin of the lower airway is a budding from the endo-
derm of the foregut.
It is obvious that the smooth muscle spasm leading to
broncho-constriction, wheezes and air flow limitation in
the respiratory system is manifested in the gastrointest-
inal tract as dysphagia when it affects the smooth mus-
cle layer in the esophagus, or colic and intestinal
obstruction when affecting the small intestine.
Even more, the circular strictures and longitudinal fur-
rows seen in the endoscopic picture of the EE are much
reminding us of the picture of bronchial smooth muscle
spasm.
Also, the mucosal irritation with cough and sputum in
the respiratory system is manifested in the EG by diar-
rhea with malabsorption and protein losing.
The documented association of the clinical picture of
GERD with asthma and vice versa can be explained at
least partly in some cases on basis of undiagnosed atopic
EE associated with atopic asthma.
The subset of children who develops atopic or allergic
asthma deserves to be differentiated as early as possible,
through the personal or family history of atopy, com-
bined if possible with testing for induced sputum eosi-
nophilia or other immunological tests as advocated by
Peter Sly and colleagues [13]. These subsets, according
to our unpublished pragmatic real-world clinical study
as well, can get much benefit from early interventions
such as allergen avoidance, or treatment courses with a
drug like ketotifen, which through not fully understood
anti-allergic or cell stabilizing mechanisms, might have
good impact on the natural evolution of the disease.
Even in adults, this is the subset of patients I expect to
be more responsive to controllers like corticosteroids,
cromones and leukotriene modifiers.
The treatment of EDD, so far is similar to that of allergic
bronchial asthma which includes avoidance of suspected
allergens and systemic corticosteroids [2,4,14-16]. Leuko-
triene modifiers, and oral cromones had also been tried
with some reports of success [17-20].
Conclusion
With regard to this apparent strong interrelation
between EDD and allergic bronchial asthma, not only in
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in embryology but also in drug therapy; might we be
justified to simplify matters to use terms like allergic
esophageal asthma or enteral asthma?
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